Meropenem Qilu (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to weakened cell walls, osmotic instability, and ultimately bacterial cell death.

The dosage of Meropenem Qilu is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. The prescriber sets the appropriate dose and infusion schedule.

Safety data for meropenem in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Meropenem Qilu, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems but offers a slightly wider gram‑negative coverage and greater stability against many β‑lactamases compared with imipenem. Choice among carbapenems depends on local resistance patterns, patient factors and specific infection sites.

Meropenem Qilu must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept refrigerated if not administered immediately.

Meropenem Qilu is supplied as a sterile powder for injection and is administered intravenously. It is typically reconstituted with a compatible diluent and infused over a prescribed period, usually 15‑30 minutes, under aseptic conditions.

Serious risks include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can be life‑threatening if not promptly recognized.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics should avoid this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid without appropriate monitoring.